drugset / Trial / NCT00196586
Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients
Phase 2
Completed
75 enrolled
French National Agency for Research on AIDS and Viral Hepatitis
Hoffmann-La Roche · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this pilot study is to evaluate efficacy and safety of addition of IL-2 to pegylated interferon alpha 2a and ribavirin in HIV-HCV coinfected patients non-responders after three months of standard therapy with pegylated interferon alpha 2a and ribavirin. IL-2 may enhance numbers and function of CD4 T lymphocytes and specific anti-HCV immune responses and could participate to the control of HCV replication
Timeline
- Start
- 2003-04
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 3e+06 iu | Subcutaneous |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Background | Ribavirin | Small molecule | — | — |